Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.60 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12043687 | 0.80 | NOTUM (0.55) | NOTUMCES1CYP2D6CYP2C9TRPA1 | |
| SCHEMBL9545365 | 0.79 | NOTUM (0.51) | NOTUMCES1CYP2D6CYP2C9TRPA1 | |
| SCHEMBL6362382 | 0.78 | CES1 (0.48) | CES1LMNATTRMAPTKDM4E | |
| SCHEMBL1048074 | 0.75 | NOTUM (1.00) | NOTUMCES1CYP2D6CYP2C9RAB9A | |
| SCHEMBL30003296 | 0.75 | NOTUM (1.00) | NOTUMCES1CYP2D6CYP2C9RAB9A | |
| SCHEMBL9545463 | 0.72 | NOTUM (0.44) | NOTUMCES1CYP2D6CYP2C9TRPA1 | |
| SCHEMBL68594 | 0.71 | NOTUM (0.72) | NOTUMCYP2D6CYP2C9RAB9AHSD17B3 | |
| SCHEMBL6362589 | 0.71 | CES1 (0.44) | CES1NPC1RAB9ALMNATTR | |
| SCHEMBL6366637 | 0.71 | NPC1 (0.46) | CES1NPC1RAB9ABRD4LMNA | |
| SCHEMBL13024432 | 0.71 | CES1 (0.48) | CES1LMNATTRMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2018-01-18 | — | — | US | disclosed |
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | AGENEBIO, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | AGENEBIO, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20100168174-A1 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20070021397-A1 | Neurocyte protective agent | EISAI CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
| WO-2006107859-A2 | DIHYDROPYRIDINE COMPOUNDS FOR NEURODEGENERATIVE DISEASES AND DEMENTIA | EISAI CO., LTD. (JP) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006107860-A2 | DIHYDROPYRIDINE COMPOUNDS AND COMPOSITIONS FOR HEADACHES | EISAI CO., LTD. (JP) | 2006-10-12 | — | — | WO | disclosed |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | EISAI CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | EISAI CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| WO-2005087226-A1 | CADASIL TREATMENT WITH CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2005-09-22 | — | — | WO | disclosed |
| WO-2003092606-A2 | CHOLINESTERASE INHIBITORS TO PREVENT INJURIES CAUSED BY CHEMICALS | EISAI CO., LTD. (JP) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003024450-A1 | METHODS FOR TREATING PRION DISEASES | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | NOTUM 2781/4885CES1 2253/4885CYP2D6 4629/4885 |
| US-20100168174-A1 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain | ACHE, CHRNA5, CHRNA2 | NOTUM 569/4885CES1 238/4885CYP2D6 1728/4885 |
| US-20070021397-A1 | Neurocyte protective agent | CHAT, GAP43, NES | NOTUM 988/4885CES1 1080/4885CYP2D6 4478/4885 |
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, BACE1, GRIN2A | NOTUM 3174/4885CES1 1013/4885CYP2D6 2032/4885 |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | ACHE, BPHL, GLA | NOTUM 622/4885CES1 2026/4885CYP2D6 2748/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | NOTUM 3174/4885CES1 1013/4885CYP2D6 2032/4885 |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | NOTUM 2287/4885CES1 688/4885CYP2D6 1808/4885 |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | ACHE, CHAT, BCHE | NOTUM 975/4885CES1 2300/4885CYP2D6 3019/4885 |
| US-20110053981-A1 | Methods and Compositions Using Cholinesterase Inhibitors | PSEN1, BACE1, PSENEN | NOTUM 1921/4885CES1 1334/4885CYP2D6 4052/4885 |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | NOTUM 2287/4885CES1 688/4885CYP2D6 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.